Annabel Samimy
Stock Analyst at Stifel
(4.34)
# 407
Out of 4,711 analysts
59
Total ratings
45.1%
Success rate
29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IVA Inventiva | Maintains: Buy | $20 → $17 | $2.35 | +623.40% | 4 | Nov 22, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $40 | $20.36 | +96.46% | 1 | Oct 8, 2024 | |
| RVNC Revance Therapeutics | Maintains: Buy | $24 → $20 | $3.09 | +547.25% | 3 | Aug 9, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $5.90 | +205.08% | 1 | Jul 3, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $7.45 | +222.15% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $7.62 | +424.93% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $42.25 | +89.35% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $122.97 | +87.04% | 8 | Mar 15, 2024 | |
| EOLS Evolus | Reiterates: Buy | $23 → $25 | $10.89 | +129.57% | 1 | Mar 8, 2024 | |
| OCS Oculis Holding AG | Initiates: Buy | $35 | $16.98 | +106.12% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $33.21 | +95.72% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $0.42 | +6,525.65% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $28 → $11 | $0.40 | +2,650.00% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $12.34 | +264.67% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $0.87 | +817.12% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.40 | +1,614.29% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $20 | $15.52 | +28.87% | 1 | Apr 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.11 | +67,467.57% | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $35.43 | -32.26% | 7 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $15 → $21 | $0.95 | +2,110.53% | 6 | Sep 18, 2019 |
Inventiva
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $2.35
Upside: +623.40%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $20.36
Upside: +96.46%
Revance Therapeutics
Aug 9, 2024
Maintains: Buy
Price Target: $24 → $20
Current: $3.09
Upside: +547.25%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $5.90
Upside: +205.08%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $7.45
Upside: +222.15%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $7.62
Upside: +424.93%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $42.25
Upside: +89.35%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $122.97
Upside: +87.04%
Evolus
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $10.89
Upside: +129.57%
Oculis Holding AG
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $16.98
Upside: +106.12%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $33.21
Upside: +95.72%
Jun 27, 2023
Reiterates: Buy
Price Target: $28
Current: $0.42
Upside: +6,525.65%
Jun 26, 2023
Downgrades: Hold
Price Target: $28 → $11
Current: $0.40
Upside: +2,650.00%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $12.34
Upside: +264.67%
Nov 10, 2022
Upgrades: Buy
Price Target: $8
Current: $0.87
Upside: +817.12%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.40
Upside: +1,614.29%
Apr 24, 2020
Initiates: Hold
Price Target: $20
Current: $15.52
Upside: +28.87%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.11
Upside: +67,467.57%
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $35.43
Upside: -32.26%
Sep 18, 2019
Maintains: Hold
Price Target: $15 → $21
Current: $0.95
Upside: +2,110.53%